Don’t miss – Page 72 – Endpoints News

SUBSCRIBE

CMO Sean Bohen joins exodus at AstraZeneca during a major R&D leadership overhaul

3 years ago

How to build a biotech unicorn: Get the star team in place, attract deep-pocket VCs, paint a big picture and raise up to $1B

3 years ago

Liz Barrett's bet on UroGen proves timely, as biotech's lead drug scores in key study

3 years ago

AstraZeneca names controversial cancer scientist José Baselga to a top R&D post in major shakeup

3 years ago

Sage's oral postpartum depression drug ticks efficacy, safety boxes in key trial, easing fears of fainting risk

3 years ago

#JPM19 starts with Eli Lilly's $8B buyout of Loxo Oncology — so who's next?

3 years ago

Shifting focus, Sanofi agrees to pay Regeneron $462M for an early wrap of their big I/O alliance

3 years ago

How much does it cost to hire a top Big Pharma exec to run a biotech? Here are 4 (very) fresh examples

3 years ago

Juno founders set their sights on creating an ‘epic’ new biotech with high-rolling investors at their back

3 years ago

Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?

3 years ago

The Atlas 5 raise a $250M 'opportunity fund' for later-stage biotech investing

3 years ago

The year of living large: A fledgling Relay Therapeutics reaps a whopping $400M venture round, with SoftBank pointing the way to a windfall

3 years ago

Novartis CAR-T chief drops out of Big Pharma, joins the great migration to a favorite biotech destination

3 years ago

Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own

3 years ago

This is the FDA’s year to shine, but can biopharma keep up as regulators continue to rev up chart-topping numbers?

3 years ago

A new analysis spotlights the top 20 drugs in the late-stage pipeline

3 years ago

'Idea Man' Paul Allen leaves behind plan to unscramble human immunology

3 years ago

Eli Lilly is going for it again, inking $2B Alzheimer's deal for tau therapies with AC Immune

3 years ago

Clive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company

3 years ago

Nasdaq celebrates epic biotech IPO success in 2018. But can the party on Wall Street rumba on?

3 years ago

Moderna skirts the reefs of disaster and sails into Wall Street with a $604M IPO bounty — but shares slide

3 years ago

AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff

3 years ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

3 years ago

Bispecifics vs CAR-T: Analysts select the big winners — and losers — at #ASH18's biggest ever datapalooza

3 years ago

First page Previous page 69 70 717273 74 Next page Last page